Skip to main content

Spectrum: Autism Research News

Benjamin Philpot explains Angelman drug prospects

 /  25 September 2013
The Presenter
Benjamin Philpot
Associate Professor, University of North Carolina, School of Medicine

Much of Benjamin Philpot’s work focuses on trying to determine the synaptic basis of Angelman syndrome and autism, as well investigating how synaptic plasticity is controlled.

On 25 September, Benjamin Philpot discussed his work investigating compounds to treat Angelman syndrome. He presented data on a pharmacological agent that activates a gene silenced in those with the disorder. Philpot is associate professor of cell and molecular physiology at the University of North Carolina School of Medicine in Chapel Hill.

You can watch a complete replay of the webinar above.

Use the comments section below to submit questions we didn’t have time to discuss during the Q&A session, or to pose follow-up questions for Philpot.

Press Policy
The Spectrum Webinar Series aims to facilitate the free exchange of ideas among autism researchers, including discussion of published and unpublished research, hypotheses and results. Members of the press may report information presented during a Spectrum webinar only if that material has already been published elsewhere or they have first obtained express written consent from the presenter.

About Webinars
Presentations by leading experts that showcase new findings, useful techniques and emerging topics in autism research. We invite questions before and during the presentations in the Comments section.